Literature DB >> 24102305

Review article: the assessment and management of chronic severe gastrointestinal dysmotility in adults.

P Paine1, J McLaughlin, S Lal.   

Abstract

BACKGROUND: The characterisation and management of chronic severe gastrointestinal (GI) dysmotility are challenging. It may cause intestinal failure requiring home parenteral nutrition (HPN). AIMS: To review the presentation, aetiology, characterisation, management and outcome of chronic severe GI dysmotility, and to suggest a pragmatic management algorithm.
METHODS: PubMed search was performed up to December 2012 using appropriate search terms, restricted to human articles and reviewed for relevance. Segmental dysmotility, acute ileus, functional syndromes and non-English articles were excluded. Evidence and recommendations were evaluated using the GRADE system.
RESULTS: In total, 721 relevant articles were reviewed. A coherent and definitive picture is hampered by overlapping classification systems using multi-modal characterisation methods, subject to pitfalls and some requiring further validation. The literature is confined to case series with no randomised trials. Fewer than 20% undergo full thickness jejunal biopsy, which are otherwise labelled idiopathic. However, in studies with up to 80% biopsy rates, neuromuscular abnormalities may be found in 90%. Between 14% and 50% will require HPN, comprising 8-14% of all HPN patients, of which 2/3 are primary/idiopathic and 1/3 secondary, with scleroderma being the leading secondary cause. Ten-year  mortality ranges from 13% to 35% and is worst in elderly scleroderma patients. Management includes limited treatments for secondary causes, prokinetics, symptom palliation, psychological support, nutrition, hydration and judicious surgery.
CONCLUSIONS: Severe dysmotility often remains idiopathic. It is rarely possible to alter disease trajectory; consequently, prognosis may be poor. Multi-disciplinary teams in a specialist setting can improve outcomes. Graded recommendations are enumerated and a pragmatic algorithm is suggested.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 24102305     DOI: 10.1111/apt.12496

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

Review 1.  Gastrointestinal and Hepatic Disease in Systemic Sclerosis.

Authors:  Tracy M Frech; Diane Mar
Journal:  Rheum Dis Clin North Am       Date:  2018-02       Impact factor: 2.670

Review 2.  Small Bowel Dysmotility, Pseudoobstruction, and Functional Correlation with Histopathology: Lessons Learned.

Authors:  Zorisadday Gonzalez; Richard McCallum
Journal:  Curr Gastroenterol Rep       Date:  2020-02-20

Review 3.  Gastrointestinal diagnosis using non-white light imaging capsule endoscopy.

Authors:  Gerard Cummins; Benjamin F Cox; Gastone Ciuti; Thineskrishna Anbarasan; Marc P Y Desmulliez; Sandy Cochran; Robert Steele; John N Plevris; Anastasios Koulaouzidis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

Review 4.  Recent Advances in the Management of Severe Gastrointestinal Dysmotility.

Authors:  Dipesh H Vasant; Simon Lal
Journal:  Clin Exp Gastroenterol       Date:  2021-05-10

5.  A Rare Case of Chronic Small Bowel Pseudo-Obstruction.

Authors:  Joyce Lim; Daniel Ashmore; Chitakattil Oommen
Journal:  Cureus       Date:  2020-05-07

6.  The management of adult patients with severe chronic small intestinal dysmotility.

Authors:  Jeremy M D Nightingale; Peter Paine; John McLaughlin; Anton Emmanuel; Joanne E Martin; Simon Lal
Journal:  Gut       Date:  2020-08-21       Impact factor: 23.059

7.  Chronic Intestinal Pseudo-Obstruction Due to Incidentally Found Thymoma.

Authors:  Daniel Castaneda; Rafael Miret; Rajaganesh Rajagopalan; Michael Castillo; Adalberto Gonzalez; Fernando Castro
Journal:  ACG Case Rep J       Date:  2021-06-02

8.  Assessment of fasted and fed gastrointestinal contraction frequencies in healthy subjects using continuously tagged MRI.

Authors:  Catharina S de Jonge; André M J Sprengers; Kyra L van Rijn; Aart J Nederveen; Jaap Stoker
Journal:  Neurogastroenterol Motil       Date:  2019-12-11       Impact factor: 3.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.